CEL-SCI Corp. (CVM)

HEALTH CARE: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

8229 BOONE BLVD . VIENNA, VA 22182

CEL-SCI is engaged in the research and development of the treatment of cancer and other diseases by utilizing the immune system, the body's defense system. Co.'s investigational therapy is Multikine (Leukocyte Interleukin, Injection), being studied in a pivotal global Phase III clinical trial. In addition, Co. is investigating an immunotherapy (Ligand Epitope Antigen Presentation System (LEAPS)-H1N1-DC) as a treatment for H1N1 hospitalized patients and as a vaccine (CEL-2000) for Rheumatoid Arthritis (in preclinical testing) using its LEAPS technology platform. Co.'s registered trademark include Multikine.

Data based on most recent fiscal year report
Market Cap18.931 Million Shares Outstanding13.92 Million Avg Volume2.326 Million
1-Yr BETA vs S&P TR1.728 Current Ratio0.39 Quick Ratio0.33
View SEC Filings from CVM instead.
Q2 2019 All Institutions Hedge Funds 1
To trade CVM now:
Filers who had this stock in their top 10: 0 0 (0.0%)
13F Filers holding this stock: 66 3 (0.31%)
Aggregate 13F shares on 06/30/2019: 5.808 Million 107.555 Thousand
Aggregate 13F shares on 03/31/2019: 3.11 Million 251.424 Thousand
Percent change: 86.73% -57.22%
Funds creating new positions: 29 1
Funds Adding to an existing position: 19 1
Funds closing out their position: 4 2
Funds reducing their position: 4
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding CVM (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

16 Thousand total shares from 2 transactions

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

CIPRIANO JOHN SENIOR VICE PRESIDENT

  • Officer
83,108 2019-09-17 4

ZIMMERMAN DANIEL H SENIOR VICE PRESIDENT

  • Officer
112,302 2019-09-04 6

KERSTEN GEERT R CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
1,102,746 2019-09-04 7

PRICHEP PATRICIA B SENIOR VICE PRESIDENT

  • Officer
202,180 2019-09-04 6

YOUNG PETER R

  • Director
21,091 2019-05-21 4

WATSON ROBERT EUGENE

  • Director
1,458 2019-05-07 2

TALOR EYAL CHIEF SCIENTIFIC OFFICER

  • Officer
0 2019-04-11 4

BAILLAVOINE BRUNO JEAN-MARIE

  • Director
0 2019-04-11 1

ESTERHAZY ALEXANDER G

  • Director
0 2017-06-12 0

DE CLARA MAXIMILIAN

  • FORMER OFFICER AND DIRECTOR
No longer subject to file 2016-08-31 0

KINSOLVING C RICHARD

  • Director
0 2014-08-06 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

CIPRIANO JOHN - Officer SENIOR VICE PRESIDENT

2019-09-17 S 8,000 $8.69 d 83,108 83,108.00 direct

KERSTEN GEERT R - Director - Officer CHIEF EXECUTIVE OFFICER

2019-09-04 A 3,492 $7.16 a 1,102,746 1,102,746.00 direct

PRICHEP PATRICIA B - Officer SENIOR VICE PRESIDENT

2019-09-04 A 2,095 $7.16 a 202,180 202,180.00 direct

ZIMMERMAN DANIEL H - Officer SENIOR VICE PRESIDENT

2019-09-04 A 2,375 $7.16 a 112,302 112,302.00 direct

CIPRIANO JOHN - Officer SENIOR VICE PRESIDENT

2019-08-28 S 8,000 $7.03 d 91,108 91,108.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments